» Articles » PMID: 20590562

Phytocannabinoids Beyond the Cannabis Plant - Do They Exist?

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2010 Jul 2
PMID 20590562
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

It is intriguing that during human cultural evolution man has detected plant natural products that appear to target key protein receptors of important physiological systems rather selectively. Plants containing such secondary metabolites usually belong to unique chemotaxa, induce potent pharmacological effects and have typically been used for recreational and medicinal purposes or as poisons. Cannabis sativa L. has a long history as a medicinal plant and was fundamental in the discovery of the endocannabinoid system. The major psychoactive Cannabis constituent Delta(9)-tetrahydrocannabinol (Delta(9)-THC) potently activates the G-protein-coupled cannabinoid receptor CB(1) and also modulates the cannabinoid receptor CB(2). In the last few years, several other non-cannabinoid plant constituents have been reported to bind to and functionally interact with CB receptors. Moreover, certain plant natural products, from both Cannabis and other plants, also target other proteins of the endocannabinoid system, such as hydrolytic enzymes that control endocannabinoid levels. In this commentary we summarize and critically discuss recent findings.

Citing Articles

Involvement of CB1R and CB2R Ligands in Sleep Disorders and Addictive Behaviors in the Last 25 Years.

Perez-Morales M, Espinoza-Abad R, Garcia-Garcia F Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006078 PMC: 11860062. DOI: 10.3390/ph18020266.


The Effects of Cannabinoids on Ischemic Stroke-Associated Neuroinflammation: A Systematic Review.

Alraddadi E, Aljuhani F, Alsamiri G, Hafez S, Alselami G, Almarghalani D J Neuroimmune Pharmacol. 2025; 20(1):12.

PMID: 39899062 PMC: 11790784. DOI: 10.1007/s11481-025-10171-z.


Utilization of Cannabidiol in Post-Organ-Transplant Care.

Koyama S, Etkins J, Jun J, Miller M, So G, Gisch D Int J Mol Sci. 2025; 26(2).

PMID: 39859413 PMC: 11765766. DOI: 10.3390/ijms26020699.


Exploring β-caryophyllene: a non-psychotropic cannabinoid's potential in mitigating cognitive impairment induced by sleep deprivation.

Lim C, Ogawa S, Kumari Y Arch Pharm Res. 2024; 48(1):1-42.

PMID: 39653971 DOI: 10.1007/s12272-024-01523-z.


Pharmacology of Non-Psychoactive Phytocannabinoids and Their Potential for Treatment of Cardiometabolic Disease.

Wainwright C, Walsh S Handb Exp Pharmacol. 2024; 287():61-93.

PMID: 39235486 DOI: 10.1007/164_2024_731.


References
1.
Rios J . Effects of triterpenes on the immune system. J Ethnopharmacol. 2010; 128(1):1-14. DOI: 10.1016/j.jep.2009.12.045. View

2.
Gertsch J . How scientific is the science in ethnopharmacology? Historical perspectives and epistemological problems. J Ethnopharmacol. 2009; 122(2):177-83. DOI: 10.1016/j.jep.2009.01.010. View

3.
. Guide to Receptors and Channels (GRAC), 4th Edition. Br J Pharmacol. 2009; 158 Suppl 1:S1-254. PMC: 2884572. DOI: 10.1111/j.1476-5381.2009.00499.x. View

4.
Gertsch J . Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action?. Commun Integr Biol. 2009; 1(1):26-8. PMC: 2633791. DOI: 10.4161/cib.1.1.6568. View

5.
Pertwee R . The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 2005; 7(3):E625-54. PMC: 2751266. DOI: 10.1208/aapsj070364. View